We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

39 hedge funds and large institutions have $37.4M invested in Cue Biopharma in 2018 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,000% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 1

363% more capital inflows, than outflows

Capital inflows: $22M | Capital outflows: $4.76M

280% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 5

34% more funds holding

Funds holding: 29 → 39 (+10)

6.16% more ownership

Funds ownership: 9.48% → 15.64% (+6.2%)

Holders
39
Holders Change
+10
Holders Change %
+34.48%
% of All Funds
0.89%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
19
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$6.46M
2
Nantahala Capital Management
Nantahala Capital Management
Connecticut
+$5.61M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$2.87M
4
Northern Trust
Northern Trust
Illinois
+$1.4M
5
State Street
State Street
Massachusetts
+$1.32M

Top Sellers

Rank Fund Capital Flow
1
First Eagle Investment Management
First Eagle Investment Management
New York
-$4.04M
2
Citigroup
Citigroup
New York
-$458K
3
Virtu Financial
Virtu Financial
New York
-$232K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$15.1K
5
Barclays
Barclays
United Kingdom
-$7.16K

CUE Hedge Fund Activity: Q2 2018 in Review

39 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q2 2018, worth a combined $37.4M — up 44% from $25.9M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new CUE positions and 1 closed out — a net gain of 10 holders — while 19 added to existing stakes and 5 trimmed.

The largest buyer was BlackRock, adding an estimated $6.46M. The largest seller was First Eagle Investment Management, cutting an estimated $4.04M.

  • 39 institutional investors held Cue Biopharma (CUE) as of Q2 2018, up from 29 in Q1 2018.
  • Funds reported $37.4M of Cue Biopharma stock for Q2 2018, up 44% quarter-over-quarter.
  • 11 funds opened new Cue Biopharma positions in Q2 2018 and 1 closed out, a net change of +10 holders.
  • The largest Cue Biopharma buyer in Q2 2018 was BlackRock, an estimated $6.46M added.
  • The largest Cue Biopharma seller in Q2 2018 was First Eagle Investment Management, an estimated $4.04M sold.

Based on aggregated 13F filings for Q2 2018.